Myeloma Research News

November 25, 2020November 25, 2020

China Approves Xgeva to Prevent Bone Events Due to Multiple Myeloma, Other Cancers

Xgeva (denosumab) has been approved by the China National Medical Products Administration (NMPA) to prevent bone problems — such as fractures, spinal cord compressions, and the need for radiation or ... Read more

November 23, 2020November 23, 2020

New $100M Program Aims to Improve Diversity in Clinical Trials

Myeloma Research News

A new $100-million program aims to improve the diversity of participants in U.S. clinical trials with the ultimate goal of achieving better health outcomes and parity in care for underserved patient ... Read more

November 18, 2020November 18, 2020

Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU

Myeloma Research News

Janssen is seeking to extend approval of its under-the-skin formulation of Darzalex (daratumumab) to include its use in combination with Pomalyst (pomalidomide) and dexamethasone to treat relapsed or refractory multiple myeloma patients who received at ... Read more

November 16, 2020November 17, 2020

Myeloma UK Calls for More Data Transparency to Safeguard Patients From COVID-19

COVID-19 News, Myeloma Research News

Myeloma UK is calling for more data transparency in government efforts to safeguard myeloma patients during the COVID-19 pandemic. This comes after results were released from its COVID-19 survey that ... Read more

November 13, 2020November 13, 2020

Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715

Myeloma Research News

ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people with relapsed or refractory multiple myeloma, a Phase ... Read more

November 11, 2020November 12, 2020

Radiation Therapy Safe for Myeloma Patients Before CAR T-cell Infusion, Study Finds

Myeloma Research News

Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma waiting for CAR T-cells to be manufactured was found to be safe and did not impact CAR T-cell ... Read more

November 9, 2020November 9, 2020

New Nirogacestat Combos to Enter Myeloma Trials, SpringWorks Says

Myeloma Research News

SpringWorks Therapeutics announced new collaborations with two companies, Pfizer and Janssen, to investigate its oral therapy candidate nirogacestat in combination with BCMA-targeting agents to treat people with relapsed or refractory multiple myeloma. ... Read more

November 6, 2020November 6, 2020

Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA

Myeloma Research News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma that uses a person’s immune cells to help combat cancer. ... Read more

November 2, 2020November 2, 2020

No More Patients Needed in GENESIS Trial of Motixafortide, Committee Says

Myeloma Research News

An independent data monitoring committee has recommended that the GENESIS Phase 3 trial evaluating motixafortide (formerly BL-8040), as a means to improve stem cell transplants in multiple myeloma, ceases enrollment ... Read more

October 30, 2020October 30, 2020

CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial

Myeloma Research News

CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond to three treatment modalities, according to additional data ... Read more

October 28, 2020October 28, 2020

‘Everybody Loves Raymond’ Cast Reunites for Virtual Fundraiser

Myeloma Research News

The cast of the hit sitcom “Everybody Loves Raymond” reunited online to honor former co-star Peter Boyle for the International Myeloma Foundation’s (IMF) 14th Annual Comedy Celebration. The fundraiser benefits ... Read more

October 26, 2020October 26, 2020

Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports

Myeloma Research News

First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data from the CASSIOPEIA trial’s second part. These findings, ... Read more

October 23, 2020October 23, 2020

Oncopeptides Will Seek Conditional Approval of Melflufen in Europe

Myeloma Research News

Oncopeptides soon will seek conditional approval of melflufen (melphalan flufenamide) in the EU for the treatment of relapsed or refractory multiple myeloma. The pharmaceutical company now is planning to submit its application ... Read more

October 21, 2020October 21, 2020

Sarclisa Triple Combo Conditionally Approved for NHS Use in England, Wales

Myeloma Research News

After first rejecting a Sarclisa (isatuximab) triple combination therapy due to cost-effectiveness concerns, the U.K.’s National Institute for Health and Care Excellence (NICE) has given conditional approval to the treatment for relapsed or ... Read more

October 19, 2020October 19, 2020

1st Patient Dosed With Investigational T-cell Therapy NEXI-002 in Phase 1/2 Trial

Myeloma Research News

NexImmune has dosed the first patient participating in its Phase 1/2 trial of NEXI-002, the company’s investigational T-cell therapy for multiple myeloma. The trial (NCT04505813), which is recruiting participants at ... Read more